Modest Increase To 2015 FDA Funds Includes $903.4 Mil. For CFSAN
This article was originally published in The Rose Sheet
Executive Summary
An omnibus spending agreement gives FDA about a 1.3% increase from its fiscal 2014 appropriation. CFSAN’s allocation of $903.4 million represents a more than 2% increase over fiscal 2014 enacted funding, consistent with the President’s budget request and the Senate’s proposed funding, but roughly $10 million less than the original House figure.
You may also be interested in...
Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
FDA Budget: Compounding Increase Paid With Construction Funding, Efficiencies
Some planned buildings on the White Oak campus for FY 2015 would not be funded and savings from program efficiencies would create the $25 million in new funding for compounding oversight, Hamburg tells House committee.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.